Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25062111 | 0.87 | TSHR (0.30) | TSHR | |
| SCHEMBL24199120 | 0.83 | ALDH1A1 (0.44) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL21788081 | 0.82 | TSHR (0.35) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL104741 | 0.82 | TSHR (0.35) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL3838045 | 0.79 | TSHR (0.64) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL17298943 | 0.78 | ALDH1A1 (0.30) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL16264337 | 0.78 | ALDH1A1 (0.39) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL598867 | 0.76 | TRPM8 (0.36) | ALDH1A1CYP3A4TSHR | |
| SCHEMBL19970035 | 0.73 | — | — | |
| SCHEMBL21788095 | 0.73 | ADRB2 (0.36) | ALDH1A1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CYP3A4 2542/4885TSHR 3319/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | ALDH1A1 2776/4885CYP3A4 2542/4885TSHR 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.